Pre-clinical studies have shown that efatutazone in combination with chemotherapy can increase cancer cell death, inhibit proliferation, and suppress cancer cell motility of particularly epidermal growth factor receptor-tyrosine kinase inhibitor (Egfr-Tki)-resistant lung adenocarcinoma cells (230–232, 264). Here, EGFR is linked to cancer.